Enquirer Consulting Group

Reachable Buyer Map

Prepared for Tom Stuart · Fletcher Spaght · September 2026
Here is the map Natoya promised. Your own site sets its boundaries: FSI works on growth for healthcare and life science companies and their investors, across medtech, diagnostics and tools, digital health, healthcare services, biopharma and transactions. So this page takes the US companies that can commission that work, splits them into groups that buy differently, and for each one shows who owns the decision and roughly how many exist. It maps the market around FSI, not FSI. Two groups have no honest public count, and the page says so rather than showing you a number. There is nothing to buy at the end of it.
Where the decision sits
Seven rows. Every number counts companies, not sites and not people, unless a row says otherwise. These rows deliberately overlap, because one company can manufacture a device, develop specifications for another and report payments to clinicians all at once. They are groups of buying behavior, not a sum, and they should never be added together.
Device manufacturers
The largest counted row and the home of your medtech practice. Diagnostic device makers register in the same federal file, so they sit inside this number rather than beside it. Research use tool makers do not register and are not in it. The split that matters here is the question on the table: the next product, the next market or the next owner. Each of those is a different engagement, bought by a different seat.
Who decides: the chief executive or chief strategy officer on a growth plan; the corporate development lead when the question is an acquisition.
About 4,900
companies, across about 5,300 registered US manufacturing sites. Company count is distinct registered firm names.
Specification developers, the design and market businesses
Companies that develop a device and manufacture none of it at that facility. What is left is design, brand and commercial, so market assessment, positioning and go to market sit at the center of the company. Teams tend to be lean, and the decision tends to sit with the founder or a single commercial lead, in one conversation rather than a committee.
Who decides: the founder or chief executive, directly.
About 3,400
companies registered as developing specifications, across about 3,550 registered sites.
Contract manufacturers and sterilizers, the supply side
The supply half of the medtech banner on your home page. These companies grow by winning the next device maker's program, so their growth question is which customers and which product categories to chase next, and whether to buy a capability or build it. That is market assessment and acquisition landscape work, sold to a business development seat.
Who decides: the chief executive or the vice president of business development.
About 2,050
contract manufacturer companies, plus about 110 contract sterilizers. Many also appear in the manufacturer row.
Companies registered to make drugs or drug ingredients in the US
Your biopharma vertical as it shows up in public data. The raw register also holds mills making medicated animal rations, medical gas fillers and imaging isotope producers, so those come out first and this row keeps only companies registered to manufacture a drug or a drug ingredient. Even then it mixes innovators with generic and over the counter makers, and nothing in the file separates them, so treat this figure as the ceiling of the row.
Who decides: the chief strategy officer or the head of business development and licensing.
About 2,150
companies holding a drug or drug ingredient manufacture registration, across about 3,500 registered US sites. Company count is distinct registered firm names, so a group with several plants is counted once.
Companies that reported payments to US clinicians or teaching hospitals last year
The commercial row. An organization appears here because it made a general payment or transfer of value to a US clinician or teaching hospital and had to disclose it. The list is published by name every year, so it is the one group on this page that names itself.
Who decides: the chief commercial officer or the head of commercial strategy.
More than 1,700
manufacturers and group purchasing organizations reported at least one general payment to a US clinician or teaching hospital in the 2025 reporting year. An organization that filed a zero payment return would not appear in it.
Healthcare investors
Your diligence and transaction work sells to corporate, private equity and venture capital investors. No public register tags a fund as healthcare focused, so any count you see for this row is an estimate. It can be built by hand from announced deals, and each investor on it sits next to a set of companies it holds.
Who decides: the deal partner, with the operating partner owning what happens after close.
No honest public count
Named here because leaving it out would make the map look more complete than it is.
Digital health, health IT and healthcare services
Two of your named verticals and a real part of the market. Software that is not a regulated device does not register with the FDA, and healthcare services organizations are spread across registers that each count something different. Neither group gets a number on this page rather than a guessed one.
Who decides: the chief executive or the head of strategy.
No honest public count
Built by hand from company signals, not from a register.
The device side, by what they actually do
The same registration file, split by the operation each site declares. A site can declare more than one, so these rows overlap by design and do not sum to the total.
Declared operationCompaniesRegistered sites
Manufacturer4,9265,267
Specification developer3,4423,565
Repackager or relabeler2,6582,769
Complaint file establishment2,2192,289
Contract manufacturer2,0622,202
US manufacturer, export only491573
Remanufacturer201208
Contract sterilizer114154

Where the openings are

1
Diagnostics and tools is the least visible market on this page. Diagnostic makers sit inside the device rows, mixed in with every other device maker, and research use tool makers never register at all. Your own bio on the FSI site names diagnostics and life science tools as your focus, and that is exactly the part of the market a list built from registers will undercount. It has to be built from company signals, not bought as a list.
2
The design and market row is the quietest buyer on this page. About 3,400 companies develop a device and manufacture none of it at that facility, so the commercial plan is the business. Lean teams and a single decision maker make the conversation short. Referrals reach them by chance, which is why a direct, named approach to the founder is the dependable route in.
3
An investor on the list is a door to a portfolio. The investor row cannot be counted, but it can be built, and each diligence relationship sits beside companies that will face the same growth questions after close. Mapping investors to what they hold turns one uncounted row into several named ones.
Built from public federal registration files and the federal database of reported payments to clinicians, all pulled in full on 22 September 2026. Counts are companies unless a row says sites, and a company count is distinct registered firm names, so a group registering several plants is counted once. Rows overlap by design and must not be added together. Counts are banded deliberately. A registration proves enumeration only, never size, quality or activity, and a segment with no credible public number says so here rather than showing one.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com